Skip to content

Tolerance Assesment of the Usage of an Analgesic Dose of Esketamine for Treatment of Moderate to Intense Pain in an Emergency Departement

Tolerance Assesment of the Usage of an Analgesic Dose of Esketamine for Treatment of Moderate to Intense Pain in an Emergency Departement

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05666869
Acronym
ESKETAMINE
Enrollment
55
Registered
2022-12-28
Start date
2022-12-12
Completion date
2023-09-01
Last updated
2022-12-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pain, Acute

Keywords

analgesia, emergency department, esketamine

Brief summary

KETAMINE has been used for several years in emergency departments for analgesic purposes. Its ease of use and its analgesic effect have been demonstrated in several studies. Nevertheless, this molecule is not devoid of side effects, in particular the very frequent occurrence of nausea, vomiting, anxiety, an overall feeling of discomfort and more rarely hallucinations, feelings of unreality, or tachycardia. Recently, ESKETAMINE, used as an anesthetic but also in the USA as an antidepressant, has obtained its Marketing Authorization in the management of moderate to severe pain. ESKETAMINE corresponds to the S-(-)-KETAMINE enantiomer. Like KETAMINE, it acts as a non-competitive antagonist of the N-methyl-D-aspartate (NMDA) receptor but unlike KETAMINE does not interact, with the sigma receptors responsible for hallucinations and delusional symptoms. ESKETAMINE aimed at anesthetic is about twice as potent as KETAMINE and would also be eliminated more quickly. Studies suggest that at equivalent doses, ESKETAMINE would be better tolerated than the KETAMINE usually used in emergency departments. In this study, the tolerance of ESKETAMINE used at analgesic doses for treatment of moderate to severe pain will be assessed in an emergency departement A wider usage of ESKETAMINE for analgesia purpose in emergency departments is expected, with a better tolerance for the patients compared to KETAMINE

Interventions

DRUGEsketamine perfusion

Analgesic dose of ESKETAMINE via a 30 minutes.intravenous perfusion

Sponsors

Association pour la Formation l'Enseignement et la Recherche du Service de l'Accueil des Urgences
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age is 18 years old or more * Moderate to severe pain as assessed by the patient with a verbal numerical rating scale (NRS) of 6/10 or more ; NRS goes from 0 (no pain) to 10 (the worst pain imaginable) * Physician has decided to use ESKETAMINE * Patient is not opposed to enroll in the study after having been informed, as attested by the physician in the patient's file

Exclusion criteria

* Adult under juridic protection, under guardianship, under curatorship * Patient unable to express his consent * Patient deprived of liberty by a judicial or administrative decision * Pregnant, parturient or nursing mother * Patients physically or mentally unable to answer the questionnaire * Typical kidney colic pain

Design outcomes

Primary

MeasureTime frameDescription
ESKETAMINE adverse reactionsFrom beginning of perfusion (T0) to patient exit of the emergency department (up to 4 hours after T0)Enumeration of the adverse reactions occuring to the patient as collected by the investigator in the patient file and by the patient in the study questionnaire

Secondary

MeasureTime frameDescription
Pain self assesment T0(b)beginning of perfusion (T0)4 points Likert pain relief scale : completely relieved ; much relieved ; a little relieved ; not relieved at all
Pain self assesment T15(a)15 minutes after the beginning of perfusion (T0 + 15 minutes)Numerical pain rating scale spanning from 0 (no pain) to 10 (the worst pain imaginable)
Pain self assesment T15(b)15 minutes after the beginning of perfusion (T0 + 15 minutes)4 points Likert pain relief scale : completely relieved ; much relieved ; a little relieved ; not relieved at all
Pain self assesment T0(a)beginning of perfusion (T0)Numerical pain rating scale spanning from 0 (no pain) to 10 (the worst pain imaginable)
Pain self assesment T30(b)30 minutes after the beginning of perfusion (T0 + 30 minutes)4 points Likert pain relief scale : completely relieved ; much relieved ; a little relieved ; not relieved at all
Patient satisfaction about his treatment (T15)15 minutes after the beginning of perfusion (T0 + 15 minutes)Self assessed 3 points Likert satisfaction scale : Very satisfied; Satisfied ; Not satisfied
Patient satisfaction about his treatment (T30)30 minutes after the beginning of perfusion (T0 + 30 minutes)Self assessed 3 points Likert satisfaction scale : Very satisfied; Satisfied ; Not satisfied
Pain self assesment T30(a)30 minutes after the beginning of perfusion (T0 + 30 minutes)Numerical pain rating scale spanning from 0 (no pain) to 10 (the worst pain imaginable)

Countries

France

Contacts

Primary ContactJulie Contenti, MD, PhD
contenti.j@chu-nice.fr0492033715
Backup ContactJocelyn Rapp, MSc
rapp.j@chu-nice.fr0492038535

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026